Acquiring Company
Tris Pharma
Acquired Company
Drug Candidate
Description
Tris Pharma, Inc. ("Tris"), a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, today announced that it has acquired rights to TRN-261 a non-opioid drug candidate that Tris intends to develop for multiple indications within acute and chronic pain.
Quick answer
Tris Pharma is acquiring Drug Candidate, announced December 7, 2022. Tris Pharma is based in Monmouth Junction, New Jersey, United States.
- How much did Tris Pharma pay for Drug Candidate?
- The deal value was not disclosed.
- What does Tris Pharma do?
- Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than..
- Where are Tris Pharma and Drug Candidate based?
- Tris Pharma is based in Monmouth Junction, New Jersey, United States.
- Who are the decision-makers at Tris Pharma?
- Fundz holds 1 contact at Tris Pharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Pharmaceutical Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Merck Completes Tender Offer To Acquire Imago Biosciences, Inc. (January 11, 2023)
- Merck To Acquire Imago Biosciences, Inc. (November 21, 2022)
- Shockwave Medical To Acquire Neovasc (January 17, 2023)
- Shockwave Medical Announces Agreement To Acquire Neovasc (January 17, 2023)
- Viatris Closes Acquisitions Of Oyster Point Pharma And Famy Life Sciences, Establishing New Viatris Eye Care Division (January 3, 2023)
- H-Cyte Completes Acquisition Of Skindisc™ Regenerative Tissue Kit From Scion Solutions, Llc (December 29, 2022)
Who to call at Tris Pharma, and when
When Tris Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Tris Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tris Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tris Pharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tris Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Drug Candidate?
Drug Candidate was acquired by Tris Pharma, based in Monmouth Junction. The deal was reported on December 7, 2022. Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Tris Pharma is privately held and operates in Healthcare.
When did Tris Pharma acquire Drug Candidate?
Tris Pharma's acquisition of Drug Candidate was reported on December 7, 2022. Tris Pharma, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Drug Candidate do?
Drug Candidate is the company acquired in this transaction. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.